PVLA News and Press, Palvella Therapeutics Inc.

BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit organizations, including the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS) ...

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malf...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 8.2% to $1.72 on volume of 989,059,874 shares NVIDIA Corporation (NVDA) fell 5.5% to $184.89 on volume of 360,807,907 shares Avalon GloboCare Corp. (ALBT) rose 114.5% to $1.09 on v...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 10.7% to $1.76 on volume of 915,226,798 shares NVIDIA Corporation (NVDA) fell 5.7% to $184.355 on volume of 298,520,855 shares Avalon GloboCare Corp. (ALBT) rose 81.8% to $0.9239 o...

2026-02-26 06:19:06 ET More on Palvella Therapeutics Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst Palvella Therapeutics launches $150M public stock offering Palvella surges on late-stage trial win for lead asset Seeking Alpha’s Quant R...

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malfo...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.6% to $1.66 on volume of 606,786,434 shares Blue Hat Interactive Entertainment Technology (BHAT) rose 6.8% to $0.0703 on volume of 273,282,515 shares Reliance Global Group Inc. (...

2026-02-24 16:21:59 ET More on Palvella Therapeutics Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst Palvella surges on late-stage trial win for lead asset Adagene, Palvella gain after FDA Fast Track Designations Seeking Alpha’s Quant Rat...

2026-02-24 16:10:01 ET Denver, Colorado - Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today’s developments are sha...

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malfo...